The middle of July has a quality that the calendar does not advertise. It is the point at which the year stops being new and is not yet nearly over. Six months are spent and six remain, and for a short while both halves are visible at once. Nicole Junkermann has long thought this a more honest vantage point than either the optimism of January or the accounting of December.
It is also a natural moment to ask what patient capital actually means, as opposed to what it sounds like. The phrase has become comfortable, which is a risk for any idea. Patience is easy to claim in a good year and hard to practise in a bad month, and the half year mark is where the difference tends to show.
The midpoint is a checkpoint, not a verdict
Half a year is long enough to have produced results and far too short to have produced meaning. This is the central difficulty of July. There is data, and it is real, and it is almost entirely uninformative about the questions that matter. A company that has had six good months has had six good months. A company that has had six difficult ones has had six difficult ones. Neither fact tells you much about whether the underlying thing is working.
The temptation at the midpoint is to treat the number as a judgement and to act on it. Nicole Junkermann has consistently argued the opposite. The midpoint is a good time to check whether the original reasoning still holds, which is a different exercise entirely. The question is not whether the results are good. It is whether the reasons you expected results are still true.
That distinction matters because the alternative is a kind of managed panic. If the midpoint is a verdict, then every midpoint requires a response, and the responses accumulate. Over enough years a portfolio managed that way is no longer an expression of anything. It is a record of reactions to Junes.
What patience actually asks of you
Patient capital is often described as though it were a matter of temperament, as if some investors were simply calmer than others. In practice it is closer to a set of habits, and the habits are more specific than the word suggests.
- Judging a company against the reasoning that led you to back it, rather than against the last quarter's number.
- Staying close enough to notice a real change, and far enough away not to react to noise.
- Accepting that the middle years of a good company are usually the least interesting ones to watch.
- Being willing to say that nothing has changed, and to say it without embarrassment.
The last of those is harder than it looks. There is a quiet pressure, particularly at a moment like the half year mark, to have something to report. Doing nothing is rarely a satisfying update. But a portfolio in which nothing needed to change is often a portfolio that was assembled well, and the discipline of saying so plainly is part of what patience costs.
Why July suits the question
The season helps, and not only because it is quiet. July removes the two things that most distort a review of this kind. The first is the pressure of a deadline, because nothing concludes in July. The second is the presence of an audience, because the people who would normally be watching are largely elsewhere. What remains is the rare chance to look at a set of decisions without needing to justify them to anyone that afternoon.
It is not an accident that the clearest thinking often happens in the weeks when the least is being demanded. Nicole Junkermann has made a habit of using the quiet part of the year for the questions that deserve more than an hour, on the grounds that no such hour will present itself in October.
There is something in the British summer in particular that reinforces the lesson. Almost nothing worth looking at in this country moves quickly. The gardens that seem effortless in July are the visible portion of a great deal of unglamorous work carried out in months when nobody was admiring them. The same is true of the landscape, of the cities, and, Nicole Junkermann would argue, of any company worth holding for a decade. What you are seeing in the good season is the result of the ordinary ones.
The virtue of not rushing
The strongest case for not rushing is not a moral one. It is practical. Rushing is expensive. A decision taken quickly at the midpoint of a year, on six months of partial evidence, has to be paid for later, usually by the people who were relying on the original plan. The cost is rarely visible at the time, which is why the habit persists.
Not rushing is also not the same as not moving. Nicole Junkermann has been careful about this distinction. Patience without judgement is simply inattention wearing better clothes. The point is to act when the reasoning changes and to hold when it does not, and to be able to tell the difference, which is a skill rather than a temperament and improves with use.
There is a version of patience that is really just avoidance, and it is worth naming, because it can look identical from the outside for a surprisingly long time. The difference is whether you are still asking. An investor who has stopped examining a position is not being patient with it. They have simply stopped noticing it, and the two only diverge when something goes wrong.
So the half year mark is worth marking, but not in the way the calendar suggests. It is not a scoreboard. It is a moment to reread your own reasoning in good light, with the diary quiet and nobody waiting for the answer, and to notice how much of it still stands. In most years, and in most portfolios, more of it stands than the noise of the last six months would have you believe. That, in July, is what patient capital looks like.
Visit the Nicole Junkermann homepage, read more about Nicole Junkermann, see the full biography of Nicole Junkermann, or return to the journal.
